Cassava Sciences Inc (SAVA NASDAQ) stock market data APIs
$1.3803
0.04(2.9%)
as of May 5, 2026
Try our APIs with
free plan!
Cassava Sciences Inc Financial Data Overview
Price chart is built with
Anychart
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Prev. Close
1.3803
Open
1.4223
High
1.4508
Low
1.3602
52 wk Range
1.36-4.98
Market Cap
115 M
Shares Outstanding
48 308 K
EPS
0
Beta
-0.84
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cassava Sciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cassava Sciences Inc data using free add-ons & libraries
Get Cassava Sciences Inc Fundamental Data
Cassava Sciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -69 296 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.3
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cassava Sciences Inc News
New
Cassava Sciences And 2 Other Promising Penny Stocks
As February begins, major U.S. stock indexes have shown a strong start, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing record highs. In this context of market optimism...
Cassava Technologies and AXON Networks Announce Strategic Partnership to Fuel AI Adoption and Innovation Among African Businesses
CAPE TOWN, South Africa, Jan. 28, 2026 /PRNewswire/ -- Cassava Technologies, a global technology leader of African heritage and AXON Networks (AXON), a global leader in intelligent network platforms, ...
Cassava Sciences drops on delay for epilepsy study
[epilepsy] Frank Brennan/iStock via Getty Images Cassava Sciences (SAVA [https://seekingalpha.com/symbol/SAVA]) fell ~14% in the premarket on Friday after the company said it will be forced to delay ...
Cassava Sciences hit with FDA request for more data on simufilam trial
[Neuron system disease] * Cassava Sciences (SAVA [https://seekingalpha.com/symbol/SAVA]) said in a filing [https://seekingalpha.com/filing/66769378]the FDA has asked for more information before all...
Get Cassava Sciences Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
